Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7816611 | 0.79 | HDAC1 (0.41) | HDAC1HDAC6 | |
| SCHEMBL17198923 | 0.75 | — | — | |
| SCHEMBL28301203 | 0.72 | — | — | |
| SCHEMBL17195015 | 0.72 | CXCR3 (0.30) | — | |
| SCHEMBL31727920 | 0.72 | ADRB3 (0.32) | — | |
| SCHEMBL30685417 | 0.68 | — | — | |
| SCHEMBL25325933 | 0.67 | — | — | |
| SCHEMBL20456688 | 0.67 | LRRK2 (0.32) | — | |
| SCHEMBL30756133 | 0.64 | HDAC1 (0.40) | HDAC1HDAC6 | |
| SCHEMBL28446333 | 0.64 | HDAC1 (0.46) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-109790149-A | PHENOXYTRIAZOLES | 豪夫迈·罗氏有限公司 | 2019-05-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566030-B2 | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators | PDK1, PDK2, PDK3 | HDAC1 1586/4885HDAC6 1128/4885 |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | HDAC1 1408/4885HDAC6 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.